13-OAHSA , CAS No.1997286-67-5

CAS: 1997286-67-5 Cat. No.: O1437267 Formula: C₃₆H₆₈O₄ Peso molecolare: 564.92

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Panoramica

13-OAHSA is one of fatty acid esters of hydroxy fatty acids (FAHFAs). 13-OAHSA increases glucose-stimulated insulin secretion (GSIS) at a high glucose concentration.

Specifications

Condizioni di conservazione di stoccaggio

Store at -20°C

Spedito in

Ice chest + Ice pads

Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.

Nomi e identificatori

• Peso molecolare: 564.92

Application Protocols

No vendor-validated protocols are provided for 13-OAHSA. The following general, non-clinical procedures can help standardize use in discovery settings:

• DMSO stock preparation

  1. Warm the vial to room temperature in a desiccator. 2) Add anhydrous DMSO to achieve 10–50 mg/mL. 3) Vortex and, if needed, sonicate briefly. 4) Filter through 0.2 µm PTFE for particulate removal. 5) Aliquot into low-bind tubes and label with lot, concentration, and date.

• Plate dispensing

  • Use acoustic or positive-displacement dispensing to achieve precise nL–µL transfers. Keep final assay DMSO ≤1% v/v unless validated otherwise. Include vehicle controls on each plate.

• Stability check (quick screen)

  • Incubate an aliquot at assay temperature for the assay duration in the intended buffer/medium. Analyze by LC–MS to confirm ≥95% area purity, or your lab’s acceptance criterion.

• LC–MS method scouting

  • Column: C18, 2.1 × 50 mm, 1.7–3 µm. Mobile A: water + 0.1% formic acid; B: acetonitrile + 0.1% formic acid. Gradient: 5–95% B over 5–10 min at 0.3–0.5 mL/min. Record positive and negative ESI.

Refer to the CoA/Spec Sheet for any item-specific instructions when available.

Biological Roles

Item-specific biological function or pathway information is not provided for 13-OAHSA. Without structural details, no definitive assignment to metabolic pathways, receptor classes, or biochemical roles can be made.

General guidance for users in biochemical research

• Prior to deploying in cellular or enzymatic assays, confirm identity and purity via orthogonal methods (e.g., HRMS plus 1H NMR), and verify absence of reactive impurities that could confound results (e.g., electrophiles, redox cyclers, metal contaminants).
• Determine solubility and stability in your assay buffers. Run pre-incubation stability tests at intended temperature and time scales using LC–MS to assess hydrolysis, oxidation, or isomerization.
• Evaluate nonspecific binding or aggregation propensity by including detergent controls (e.g., 0.01–0.05% nonionic surfactant), dynamic light scattering, or counterscreens to exclude promiscuous mechanisms.
• If fluorescence readouts are used, assess intrinsic fluorescence or quenching at assay wavelengths to rule out optical interference.

Note: Aladdin products are for research use only. No medical or clinical applications are claimed or supported.

Buffer Applications

Not typically applicable. 13-OAHSA is supplied as a small-molecule/compound library item rather than a buffering reagent. No pKa or buffer capacity data are available.

Practical notes if buffers will be used in assays

• If preparing aqueous working solutions, use a compatible biological buffer (e.g., phosphate, HEPES, or Tris) appropriate to your assay pH and ionic strength. Keep organic co-solvent content low (typically 0.1–2% DMSO or ethanol) to maintain solubility.
• Check compound stability across intended pH. Run accelerated stability checks at low and high pH bounds to detect decomposition.
• Filter-sterilize working solutions where sterility is required; verify compound integrity post-filtration.

Green Alternatives

Because the structure and solvent compatibility of 13-OAHSA are not disclosed here, specific greener process recommendations cannot be tailored to this molecule. Nonetheless, for common operations involving small molecules, consider the following greener choices where appropriate:

• Reaction solvents: Replace dichloromethane/THF with 2-MeTHF, cyclopentyl methyl ether (CPME), or ethyl acetate when reaction performance allows.
• Workup/extraction: Prefer EtOAc or MTBE over chlorinated solvents; use heptane instead of hexane to reduce n-hexane exposure.
• Chromatography: Use greener solvent systems (heptane/EtOAc, toluene/EtOAc) and implement dry-loading to minimize solvent usage. Consider supercritical CO2 for scalable separations when feasible.
• Stock solutions and assays: Keep DMSO content minimal consistent with solubility to reduce solvent load; consider bio-based ethanol as an alternative co-solvent when compatible.
• Energy: Conduct reactions at ambient temperature and use flow or microwave methods to shorten residence times where applicable.

Trade-offs (general)

• 2-MeTHF/CPME are less miscible with water than THF, which affects phase behavior and reaction rates; peroxide formation must still be monitored for ethers. EtOAc is safer than DCM but may give different selectivity and higher boiling points that impact recovery.

Always confirm that greener alternatives meet solubility, rate, selectivity, and stability requirements for your specific substrate.

Pharmaceutical Uses

No excipient or pharmacopeial status is provided for 13-OAHSA, and no formulation role is specified. This product is offered strictly for research use only and is not intended for human or veterinary use, clinical diagnostics, or as an API/excipient.

If used in pre-formulation research (general guidance)

• Establish solubility profile in common vehicles (aqueous buffers, PEG 400, polysorbates, lipids) and determine chemical stability (oxidation, hydrolysis) and photostability where relevant.
• Quantify partitioning (shake-flask logD at pH 6.5/7.4) and protein binding to anticipate exposure in in vitro systems.
• For solid forms, characterize polymorphism/solvation by PXRD/TGA/DSC if material behavior suggests multiple forms.

Documentation

• No pharmacopoeial monograph or compliance claims are made for this item. Any GMP-related or regulatory development would require separate sourcing and qualification.

Physical Properties

Item-specific properties

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Purity/grade: Not specified for this item; refer to CoA/Spec Sheet.

Thermophysical and solution data (literature/general guidance)

• Because structure identifiers are not provided here, numerical physical constants (bp, mp, density, logP, pKa, refractive index, UV cutoff/ε) cannot be assigned. Consult the item’s CoA/SDS for measured values and handling limits.

Practical guidance for use when properties are unknown

• Initial solubility screening: start with anhydrous DMSO (10–50 mg/mL stock), then dilute into assay media or organic solvents as needed. If precipitation occurs on aqueous dilution, add co-solvent (e.g., 0.5–2% DMSO or ethanol) while vortexing.
• If the compound is lipophilic, expect slower dissolution; warm slightly (≤40 °C) and sonicate briefly. Avoid prolonged heating.
• If a UV–vis method is desired but λmax is unknown, record a quick scan (200–400 nm) at low concentration to select monitoring wavelengths.
• For LC–MS method scouting with unknown pKa/logP, bracket with: (a) reversed-phase C18, water/acetonitrile + 0.1% formic acid; (b) same with 5–10 mM ammonium bicarbonate (pH ~8) for negative/positive switching.
• Hygroscopicity, volatility, and peroxide formation tendencies are unknown; store tightly sealed at −20 °C as provided and minimize headspace.

Quality and Grades

Item-specific quality

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

Guidance on grades (general)

• Research chemical/library grade: Typically intended for discovery workflows (screening, reference spiking, exploratory synthesis). Specifications often focus on identity confirmation (NMR/HRMS) and assay purity (HPLC/UPLC-UV/ELSD). Low-UV or LC–MS suitability may be indicated where relevant.
• HPLC/UPLC purity vs. assay by area: Be aware that assay by peak area can differ from weight % when non-UV-absorbing components or salts are present. Request the detailed chromatogram and method (wavelength, gradient, column) if method transfer is required.
• Stabilizers/salt forms: If the item is a salt, solvate, or stabilized formulation, this will affect MW calculations and solution prep; verify on the CoA.

What to request for this SKU

• CoA documents detailing: structure confirmation (at least 1H NMR and MS), purity method and result, water/residual solvent content (KF/GC), and, if applicable, optical rotation or enantiomeric ratio.
• If intended for quantitative analytical use, request a batch-specific purity-corrected concentration factor for solution standard preparation.

Trace impurities and metals

• Metal content, peroxide content, and UV cutoff: Not specified for this item; refer to CoA/Spec Sheet.

Reaction and Applications

Manufacturer applications

• Not specified in the catalog entry beyond inclusion in a small-molecule/compound library.

How this item may be used (general, non-clinical)

• Reference standard: Prepare calibrated solutions for LC–MS/UPLC method development, retention time locking, or spike-recovery studies after identity/purity verification.
• Screening workflows: Suitable for exploratory biochemical, biophysical, or materials screens where structural identity and purity are confirmed. Define plate maps and DMSO final concentrations to minimize assay artifacts.
• Synthetic context: If the compound has orthogonal functional groups (confirm from the CoA), it may serve as a building block for SAR expansion, probe derivatization, or conjugation chemistry.

Analytical considerations

• Establish a stability-indicating method (e.g., RP-LC with dual-wavelength detection) to monitor degradation during storage and assay incubation.
• If chromophores are unknown, add an ELSD or MS detector for universal detection during QC.

Good practices

• Document batch/lot number, solvent, and concentration on all plates/vials. Validate identity after any transfer or lyophilization step.
• For plate-based screens, include vehicle controls, edge-well controls, and counterscreens to triage compound-related assay interference (fluorescence quench/enhance, redox cycling, aggregation).

Reaction Conditions

No reaction condition preferences can be specified for 13-OAHSA without disclosed structure or functional groups.

General guidance when conditions are unknown

• Solvent: Begin scouting with common platforms—polar aprotic (DMF, DMSO, MeCN), protic (MeOH, iPrOH), and ethers (THF, 2-MeTHF)—and monitor solubility and stability.
• Temperature: Start at ambient temperature; escalate cautiously. Use in situ monitoring (TLC/UPLC) to detect decomposition.
• Catalysis: If heteroatom functionality is suspected, transition-metal catalysis (Pd, Cu) or organocatalysis may be compatible, but always conduct small-scale feasibility tests first.
• Atmosphere: Default to inert atmosphere (N2/Ar) until air/moisture tolerance is confirmed.
• Workup: Choose quench and extraction protocols that avoid extreme pH unless stability is demonstrated.

Analytical controls

• Track mass balance and impurity formation by LC–MS; retain aliquots at key time points to build a stability map.

Expected yields, rate laws, and precise conditions cannot be provided here; consult the CoA/Spec Sheet once structure is available.

Safety and Handling

Regulatory and GHS

• Signal word: Not specified for this item; refer to SDS.
• H-statements: Not specified for this item; refer to SDS.
• GHS classification and pictograms: Not specified for this item; refer to SDS.

General laboratory precautions (defer to SDS for authoritative guidance)

• Handle in a chemical fume hood using standard PPE: lab coat, safety glasses, and appropriate chemically resistant gloves (e.g., nitrile). Avoid inhalation of dust/aerosols and direct skin contact.
• Prevent cross-contamination by using dedicated spatulas, weighing boats, and clean benches. Cap containers promptly to limit moisture/air exposure.
• Unknown incompatibilities: segregate from strong oxidizers and strong acids/bases until compatibility is confirmed from the SDS. Avoid ignition sources.

First-aid overview (generic)

• Inhalation: Move to fresh air; seek medical attention if symptoms persist.
• Skin contact: Wash with soap and water; remove contaminated clothing.
• Eye contact: Rinse cautiously with water for several minutes; remove contact lenses if present and easy to do; seek medical attention if irritation continues.
• Ingestion: Rinse mouth; do not induce vomiting unless directed by medical personnel; seek medical advice.

Spill and waste

• Small spills: Absorb with inert material, collect in suitable container for disposal in accordance with local regulations.
• Waste: Dispose of contents/container as chemical waste; consult the SDS for U.S. RCRA/EU waste codes if applicable.

Note: Always consult the item-specific SDS before first use.

Solvent Selection

Item-specific solubility/miscibility

• Not specified for this item; refer to CoA/Spec Sheet.

General strategies for small-molecule library compounds

• Stock solutions: Start with anhydrous DMSO (10–50 mg/mL) for convenient aliquoting and assay dilution. For non-polar analytes, consider DMF or 2-methyltetrahydrofuran (2-MeTHF) for synthetic workflows.
• Aqueous work: If aqueous compatibility is needed, prepare intermediate stocks in DMSO or ethanol and dilute into buffer while vortexing to avoid precipitation. Maintain final organic co-solvent at 0.1–2% v/v as allowed by your assay.
• Partition behavior unknown: When developing extraction or purification methods, test both polar (MeOH, MeCN) and less polar (EtOAc, MTBE) organic phases.

Comparison notes (general)

• DMSO vs DMF: DMSO is preferred for bioassay stocks due to lower volatility and common assay tolerance; DMF may offer improved solvency for some lipophilic or base-sensitive compounds but is more hygroscopic and has stronger odor concerns.
• MeCN vs MeOH in LC: MeCN often gives lower backpressure and sharper peaks; MeOH provides different selectivity and better solvency for some polar compounds.

Practical tips

• Filter solutions (0.2 µm PTFE) if particulate forms. Avoid adsorption by pre-rinsing filters/vials when analyte lipophilicity is suspected.
• Record exact solvent, concentration, and any observed solubility limits in your ELN for reproducibility.

Storage and Reconstitution

Item-specific storage

• Storage conditions: Store at −20 °C (from Product Data).
• Shipping: Ice chest + ice pads (from Product Data).

General best practices

• Upon receipt: Allow the sealed container to equilibrate to room temperature in a desiccator before opening to prevent condensation.
• Packaging: Keep tightly capped. Minimize headspace and moisture exposure. If supplied as a solution, store in inert-gas-flushed vials when possible.
• Light/air sensitivity: Not specified for this item; if uncertain, protect from light and handle under inert atmosphere for long-term stability.

Reconstitution (when solid, general guidance)

• Prepare a concentrated stock in anhydrous DMSO (e.g., 10–50 mg/mL). Vortex and sonicate briefly if needed. Filter (0.2 µm PTFE) if particulates persist.
• Make single-use aliquots to avoid repeated freeze–thaw. Record concentration and date.

Freeze–thaw guidance

• Avoid multiple freeze–thaw cycles. Thaw at room temperature; do not heat above 40 °C. Discard aliquots showing precipitation or discoloration unless verified acceptable by analysis.

Stability limits

• Retest/expiry period, water content, and degradation pathways: Not specified for this item; refer to CoA/Spec Sheet.

For research use only. Not for human or veterinary use.

Structure and Identity

Item-specific facts (from Product Data)

• Product name: 13-OAHSA (SKU: O1437267)
• CAS: 1997286-67-5
• Storage: Store at −20 °C
• Shipping: Ice chest + ice pads
• Category: Small molecules and compound library (全部 / 可售 / 小分子和化合物库)
• Research use only

Structure identifiers

• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.

Notes on identity

• This listing does not include definitive structural descriptors. For unambiguous identification (e.g., for regulatory reporting, LC–MS method setup, or informatics registration), obtain the item-specific CoA/Spec Sheet from Aladdin Scientific or contact technical support with the CAS above.
• If 2D/3D structure files (SDF/MOL) are required for screening or LIMS registration, request the supplier structure package referencing SKU O1437267.

Synthetic Utility

Item-specific functional groups and reactivity are not disclosed for 13-OAHSA in this listing; therefore, no targeted synthetic roles can be assigned.

General considerations for using library compounds in synthesis

• If the structure contains orthogonally protected functionalities, it may serve as a building block for structure–activity relationship (SAR) elaboration. Verify functional group tolerance and protection schemes via NMR/IR/MS before planning steps.
• When repurposing a screening compound for synthesis, confirm counterion/solvate content (which impacts stoichiometry) and assess impurity profile to avoid side reactions.
• For scale-up or multistep usage, establish a robust purification method (flash chromatography or crystallization) and a stability-indicating analytical method to track degradation during steps.

Tip

• Obtain the structural file and CoA/Spec Sheet from Aladdin Scientific to define feasible transformations and anticipate chemoselectivity issues.

Target Specificity

Not applicable. 13-OAHSA is not supplied as an antibody, protein, or oligonucleotide reagent, and no target-specific binding information (antigen, epitope, isotype, species reactivity) is provided. For small-molecule screening, any target engagement or selectivity must be determined empirically by the user using validated assays.